Quest diagnostics debuts melanodal predict™ test, personalizing melanoma risk prediction to help patients forgo invasive surgery

Based on technology from skylinedx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer patients classified as low-risk by melanodal predict are shown to have survival rate of over 90 percent  secaucus, n.j., and san diego , feb. 13, 2024 /prnewswire/ -- quest diagnostics (nyse: dgx), the nation's leading provider of diagnostic information services, today announced the launch of melanodal predict™, a highly advanced predictive gene expression test to help personalize treatment decisions for patients with melanoma, the deadliest form of skin cancer and one of the most common cancers in the united states.1 dermatologists and other providers nationwide may begin ordering the test today from quest diagnostics, as well as through dermpath diagnostics, quest's subspecialty pathology business.
DGX Ratings Summary
DGX Quant Ranking